Related Experiment Videos
Pediatric pearls from the AAD Annual Meeting
1Department of Dermatology & Cutaneous Surgery, University of Miami, Florida.
Cutis
|September 30, 2017
Insights
This article presents new clinical insights and literature in pediatric dermatology from the 2017 American Academy of Dermatology meeting. It offers practical guidance for managing common and rare pediatric skin conditions.
Area of Science:
- Pediatric Dermatology
- Clinical Dermatology
- Dermatology Literature
Background:
- The 2017 Annual Meeting of the American Academy of Dermatology (AAD) in Orlando, Florida, served as a platform for disseminating cutting-edge information.
- Focus on novel clinical pearls and emerging literature relevant to pediatric dermatology practice.
Framework:
- Compilation of key takeaways and highlights from expert presentations and discussions.
- Emphasis on practical, actionable information for clinicians treating pediatric patients.
Implementation:
- Summarizes practical clinical pearls for diagnosing and managing pediatric skin conditions.
- Highlights emerging research and treatment modalities in pediatric dermatology.
Implications:
- Aims to enhance the clinical practice of pediatric dermatologists and general dermatologists.
- Facilitates the integration of the latest advancements into patient care for improved outcomes.
Abstract:
This article summarizes novel pediatric dermatology clinical pearls and emerging literature highlights compiled from the 2017 Annual Meeting of the American Academy of Dermatology in Orlando, Florida.
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
302
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
302
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
351
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
351
01:29Drug Dosing: Infants and Children
371
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
371
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
354
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
354
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
276
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
276
01:19Standards of Care II
1.1K
Nurses bear specific legal responsibilities under several federal statutes, including:
1.1K